In the past week, PTCT stock has gone up by 15.75%, with a monthly gain of 16.32% and a quarterly surge of 26.54%. The volatility ratio for the week is 6.63%, and the volatility levels for the last 30 days are 5.15% for PTC Therapeutics Inc The simple moving average for the last 20 days is 12.05% for PTCT’s stock, with a simple moving average of 32.82% for the last 200 days.
Is It Worth Investing in PTC Therapeutics Inc (NASDAQ: PTCT) Right Now?
PTCT has 36-month beta value of 0.64. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTCT is 74.40M, and currently, short sellers hold a 5.74% ratio of that float. The average trading volume of PTCT on October 24, 2024 was 637.33K shares.
PTCT) stock’s latest price update
PTC Therapeutics Inc (NASDAQ: PTCT)’s stock price has gone rise by 8.04 in comparison to its previous close of 39.32, however, the company has experienced a 15.75% increase in its stock price over the last five trading days. prnewswire.com reported 2024-10-18 that – Opinion to be reviewed by European Commission – WARREN, N.J., Oct. 18, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne Muscular Dystrophy (nmDMD) following re-examination.
Analysts’ Opinion of PTCT
Robert W. Baird, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $44. The rating they have provided for PTCT stocks is “Outperform” according to the report published on September 04th, 2024.
UBS gave a rating of “Buy” to PTCT, setting the target price at $47 in the report published on August 26th of the current year.
PTCT Trading at 19.18% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.60% of gains for the given period.
Volatility was left at 5.15%, however, over the last 30 days, the volatility rate increased by 6.63%, as shares surge +15.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.29% upper at present.
During the last 5 trading sessions, PTCT rose by +15.75%, which changed the moving average for the period of 200-days by +41.65% in comparison to the 20-day moving average, which settled at $37.91. In addition, PTC Therapeutics Inc saw 54.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Gravier Pierre, who sale 2,269 shares at the price of $34.02 back on Jul 16 ’24. After this action, Gravier Pierre now owns 53,531 shares of PTC Therapeutics Inc, valued at $77,200 using the latest closing price.
ZELDIS JEROME B, the Director of PTC Therapeutics Inc, sale 20,000 shares at $38.24 during a trade that took place back on May 22 ’24, which means that ZELDIS JEROME B is holding 14,500 shares at $764,800 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.78 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.53. The total capital return value is set at -0.15.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated -0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.38. The debt to equity ratio resting at -0.31. The interest coverage ratio of the stock is -1.93.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 5.1. When we switch over and look at the enterprise to sales, we see a ratio of 3.34. The receivables turnover for the company is 4.81for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
To put it simply, PTC Therapeutics Inc (PTCT) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
